NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
European Hematology Association Congress (EHA) 2019 – STRO-001 Poster
Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Please Click the Link, EHA_2019 STRO-001 poster to enlarge.
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL) STRO-001 is the first antibody-drug conjugate generated with Sutro’s novel cell-free protein synthesis...
European Hematology Association (EHA) 2019 – STRO-001 Abstract
Preliminary Results Of A Phase 1 Dose Escalation Study Of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Abstract PS1071 BackgroundCD74 is expressed on B cells throughout differentiation and is an...
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary...
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical Trial Underway in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO,...
American Association for Cancer Research (AACR) 2019 – STRO-002 Abstract 3897
American Association for Cancer Research (AACR) 2019 Abstract 3897: Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers.
American Association for Cancer Research (AACR) 2019 – STRO-002 Poster
American Association for Cancer Research (AACR) 2019 A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug Conjugate, In Patients With Advanced Epithelial Ovarian Cancer (Including...
American Association for Cancer Research (AACR) 2019 – STRO-001 Poster
A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In Patients With Advanced B-Cell Malignancies, NCT03424603
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central...
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April 1, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
